Last reviewed 2026-04-20 · How we verify

Tensigradyl (GUABENXAN)

Phase 2 active Small molecule

Tensigradyl (generic name: GUABENXAN) is a guabenxan drug. It is currently in Phase 2 development.

Tensigradyl works by binding to specific biological molecules to produce a therapeutic effect.

Tensigradyl (GUABENXAN) is a small molecule drug in the guabenxan class, but specific details about its target and mechanism of action are unknown. Its commercial status and approved indications are also unclear. As a small molecule, it is likely to work by interacting with specific biological molecules to produce a therapeutic effect. Further information about its pharmacokinetic properties, such as half-life and bioavailability, is not available. The current owner and generic manufacturers of Tensigradyl are also unknown.

Likelihood of approval

15.3% vs 15.3% industry baseline

If approved by FDA: likely 2031–2034

Steps remaining: Phase 3 → NDA/BLA submission

Confidence: Medium

Why this estimate

Baseline phase 2 → approval rate +15.3pp
Industry-wide phase 2 drugs reach approval ~15.3% of the time (BIO/Informa 2023 industry benchmark across all therapeutic areas).

Predicted approval windows by jurisdiction (conditional on FDA approval)

Regulator	Country	Likely year	Lag vs FDA
FDA	US	2031–2034	—
EMA	EU	2032–2035	+0.7 yr
MHRA	GB	2032–2035	+0.7 yr
Health Canada	CA	2032–2036	+0.9 yr
TGA	AU	2032–2036	+1.2 yr
PMDA	JP	2032–2036	+1.5 yr
NMPA	CN	2033–2037	+2.3 yr
MFDS	KR	2032–2036	+1.4 yr
CDSCO	IN	2032–2037	+1.8 yr
ANVISA	BR	2033–2037	+2.3 yr

Hover any row for the lag rationale. Lag estimates are reduced when the drug has FDA Breakthrough or EMA PRIME designation (sponsors file globally in parallel).

Estimate based on the BIO/Informa industry phase transition rates plus per-drug modifiers for therapeutic area, sponsor type, FDA designations, mechanism, and trial design. Per-jurisdiction lags from Tufts CSDD international approval studies. Not investment, clinical or regulatory advice. Methodology: /methodology#likelihood.

At a glance

Generic name	GUABENXAN
Drug class	guabenxan
Modality	Small molecule
Therapeutic area	Other
Phase	Phase 2

Mechanism of action

Imagine your body's cells are like a city, and Tensigradyl is a key that unlocks a specific door to allow the right things to happen. By binding to these molecules, Tensigradyl helps to restore balance and normal function to the cells, which can help to treat various diseases.

Approved indications

No approved indications tracked.

Common side effects

No common side effects on file.

Competitive intelligence

For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:

Tensigradyl CI brief — competitive landscape report
Tensigradyl updates RSS · CI watch RSS

Frequently asked questions about Tensigradyl

What is Tensigradyl?

Tensigradyl (GUABENXAN) is a guabenxan drug.

How does Tensigradyl work?

Tensigradyl works by binding to specific biological molecules to produce a therapeutic effect.

What is the generic name of Tensigradyl?

GUABENXAN is the generic (nonproprietary) name of Tensigradyl.

What drug class is Tensigradyl in?

Tensigradyl belongs to the guabenxan class. See all guabenxan drugs at /class/guabenxan.

What development phase is Tensigradyl in?

Tensigradyl is in Phase 2.

Drug class: All guabenxan drugs
Therapeutic area: All drugs in Other

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing